Skip to content
Clinical ResearchResearch compound

Gonadorelin (Factrel / Lutrelef)

Synthetic GnRH hormone that starts the production of sex hormones; a prescription medicine in Europe, banned in sport.

Gonadorelin (Factrel / Lutrelef) vial

DETAILED OVERVIEW

What is Gonadorelin (Factrel / Lutrelef)?

Gonadorelin (Factrel, Lutrelef) is a synthetic copy of GnRH, a hormone made in the brain, which via the pituitary gland starts the testicles' production of testosterone and sperm. In the United States it was approved for a diagnostic test and then withdrawn in 2008 for commercial rather than safety reasons; in Europe, Lutrelef is available to treat patients with hormone deficiency.

After steroid use, athletes try it to restart their own production, but the hormone is broken down very quickly, a single injection has limited effect, and only a pump can imitate the natural rhythm. When the signal is continuous, the receptors become insensitive and the production of sex hormones stops. Side effects include hypersensitivity (rarely anaphylaxis), reactions at the injection site and headache; self-administration with a pump also carries a risk of infection. It cannot be used with hormone-sensitive tumors. It is banned year-round in competitive sport. In humans it has mainly been studied in men with hormone deficiency, in smaller studies.

Mechanism

Stimulates the pituitary GnRH receptor; more testosterone

Half-life

~10-40 min (very short – pulsatility pattern is essential)

Onset

LH/FSH spike 15-60 min after SC

Legal status

FDA Factrel withdrawn 2008; EMA Lutrelef Ferring Rx (pulsatile-pump hypothalamic hypogonadism); WADA S2 Peptide Hormones banned

Data console

Lab data

Androgenic:AnabolicN/A (hypothalamic peptide replica, NOT AAS)
AR bindingPituitary GnRH-R (LHRH-R) Kd ~1-5 nM, high-affinity…
Active half-life~10-40 min (parent peptide active; metabolite fragments inactive)
Detection windowWADA-accredited LC-MS/MS sparse – urinary peptide detection 12-24 h (due to very short t1/2). Detection confounded by endogenous GnRH baseline.
AromatizationIndirect – GnRH → LH/FSH → testicular Test → secondary peripheral E2 conversion (CYP19 aromatase). Magnitude similar to HCG rebound; moderate on a pulsatile protocol.
HepatotoxicityNone – peptide SC injection.

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Hypersensitivity reactions, including rare anaphylaxis and antibody formation with repeated parenteral dosing (documented in FDA Factrel labeling: generalized urticaria, bronchospasm).
  • Injection-site reactions: pain, redness, itching, swelling, rarely phlebitis; with pulsatile-pump protocols, ongoing cannula-site inflammation and infection risk.
  • Headache, flushing, mild dizziness and nausea, often immediately post-injection, transient.
  • Abdominal pain and discomfort, less commonly gastric complaints (reported in FDA Factrel labeling).
  • With continuous (non-pulsatile) or prolonged dosing, paradoxical GnRH-receptor downregulation and desensitization: LH/FSH suppression and falling testicular testosterone (the chemical-castration mechanism of GnRH-agonist therapy).
  • With pulsatile-pump protocols, overstimulation from increased gonadotropin drive: multiple follicular development and risk of ovarian hyperstimulation in women; transient secondary estradiol rise in men.

Contraindications · 6

  • Known hypersensitivity to gonadorelin or GnRH analogues (prior anaphylactic or severe allergic reaction).
  • Hormone-sensitive tumor or suspicion thereof (gonadotropin- or sex-hormone-dependent tumor) where LH/FSH stimulation is contraindicated.
  • Pituitary adenoma, especially prolactinoma or gonadotroph tumor: GnRH stimulation carries a risk of pituitary apoplexy and abrupt hormone surge.
  • Concurrent GnRH-agonist therapy (leuprolide/Lupron, goserelin/Zoladex): receptor-occupancy overlap and amplification of paradoxical receptor downregulation – not recommended.
  • Pregnancy and breastfeeding: no established safety, axis stimulation not indicated; in fertility treatment only under endocrinologist supervision.
  • Not indicated for self-treatment as AAS-PCT: pulsatile pump is impractical for self-injection, bolus protocol is evidence-poor, and lack of sterile technique creates infection risk.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Gonadorelin (Factrel / Lutrelef)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.